Great Lakes Advisors LLC Sells 73 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Great Lakes Advisors LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 4.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,445 shares of the biopharmaceutical company’s stock after selling 73 shares during the period. Great Lakes Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Clearstead Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 197.6% during the third quarter. Clearstead Advisors LLC now owns 4,518 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 3,000 shares during the last quarter. Metis Global Partners LLC boosted its position in Alnylam Pharmaceuticals by 8.7% during the 3rd quarter. Metis Global Partners LLC now owns 4,288 shares of the biopharmaceutical company’s stock worth $759,000 after acquiring an additional 342 shares during the period. Arizona State Retirement System lifted its holdings in shares of Alnylam Pharmaceuticals by 0.5% during the 3rd quarter. Arizona State Retirement System now owns 33,973 shares of the biopharmaceutical company’s stock valued at $6,017,000 after buying an additional 153 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 12.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,479 shares of the biopharmaceutical company’s stock valued at $9,294,000 after buying an additional 5,980 shares during the last quarter. Finally, Privium Fund Management B.V. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $3,546,000. Institutional investors and hedge funds own 93.98% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 30,000 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the completion of the transaction, the director now directly owns 16,029 shares of the company’s stock, valued at approximately $3,125,655. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ALNY. Royal Bank of Canada dropped their price target on Alnylam Pharmaceuticals from $235.00 to $230.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st. Evercore ISI dropped their price objective on shares of Alnylam Pharmaceuticals from $252.00 to $210.00 in a research report on Tuesday, October 10th. Oppenheimer downgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 11th. Finally, Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $175.00 to $183.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $230.95.

View Our Latest Stock Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $172.18 on Wednesday. The stock has a market capitalization of $21.61 billion, a price-to-earnings ratio of -41.59 and a beta of 0.43. Alnylam Pharmaceuticals, Inc. has a 52-week low of $148.10 and a 52-week high of $227.91. The company has a 50-day moving average of $183.65 and a two-hundred day moving average of $180.00.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.